Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151418 · ClinicalTrials.gov registry record
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 2,313
- Enrollment target
NCT06151418: Completed study, sponsored by Pfizer.
NCT06151418 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 2,313 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06151418 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 2,313 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about- for how long are NHTs taken by men to treat mCSPC. NHTs in this study include study medicines: * abiraterone, * apalutamide, * enzalutamide. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Metastatic cancer is a cancer that has spread to other parts of the body. Most prostate cancers need male hormones to grow. When cancer cells respond to treatment that lowers male hormones, this is known as castration-sensitive prostate cancer. This is a real-world study, not a clinical trial. This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from National Veteran's Affairs (VA) Health Care Network. The study will include patients' information from the database for men who: * were identified to have mCSPC. * started treatment with NHT for mCSPC. * were 18 years of age or older at start of NHT. Men in this study will be taking NHT for treatment of their mCSPC. The study will explain: * how long men take the therapy. * how long it takes to start next therapy. This study will use patient information about medications and treatments from VA data. This study will use information one year before start of NHT until information is available.
Primary Outcome
DOT was defined as the time from the index date to the date of NHT discontinuation for any reason. Discontinuation of the current NHT was defined as a treatment gap of at least 90 days (the last day with days' supply before the gap as discontinuation date), the initiation of a new therapy, or death, whichever came first. Initiation of a new therapy was defined by switching to a different NHT, switching to or augmentation with different therapies. Participants who did not experience discontinuati
Interventions
- DRUG Novel hormonal therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,313 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2024-04-23 |
What the finished NCT06151418 record still lists
NCT06151418 is an observational study that tracks outcomes without assigning an intervention. Its 2,313 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Novel hormonal therapy is the first listed.
NCT06151418 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06151418 about?
NCT06151418 is a clinical study titled "A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces". The purpose of this study is to learn about- for how long are NHTs taken by men to treat mCSPC. NHTs in this study include study medicines: * abiraterone, * apalutamide, * enzalutamide. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps ma...
What is the current status of trial NCT06151418?
This trial is currently completed. The enrollment target is 2,313 participants. The study started on 2023-11-22. Estimated completion is 2024-04-23.
What interventions are being tested in trial NCT06151418?
The interventions under investigation include: Novel hormonal therapy (DRUG).
Who is sponsoring clinical trial NCT06151418?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05485961 · 2,310 participants · Phase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
- NCT05700760 · 2,320 participants · NA
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
- NCT06824194 · 2,320 participants · Phase 3
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI